2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lung Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Small Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Interventions
Cisplatin
116
Radiotherapy
84
Paclitaxel
77
Fluorouracil
62
Carboplatin
41
Drug Therapy
38
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
Neoadjuvant Therapy
24
Oxaliplatin
23
toripalimab
22
sintilimab
19
camrelizumab
19
Radiation
19
Esophagectomy
18
Capecitabine
17
130-nm albumin-bound paclitaxel
17
Surgical Procedures, Operative
16
Nivolumab
16
Leucovorin
15
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
Immune Checkpoint Inhibitors
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Histamine Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled